Dermal Cell News Volume 6.35 | Oct 5 2020

    0
    40








    2020-10-05 | DCN 6.35


    Dermal Cell News by STEMCELL Technologies
    Vol. 6.35 – 5 October, 2020
    TOP STORY

    Staphylococcus aureus Second Immunoglobulin-Binding Protein Drives Atopic Dermatitis via IL-33

    In vitro human keratinocyte cell culture, ex vivo human skin organ explants and the eczema prone Nc/Tnd mouse were used as model systems to assess type-2 promoting immune responses to S. aureus.
    [Journal of Allergy and Clinical Immunology]

    AbstractFull Article

    How to prioritize and manage your research projects
    PUBLICATIONSRanked by the impact factor of the journal
    DERMAL STEM CELLS & TISSUE REGENERATION

    Heterogeneity in VEGF Receptor-2 Mobility and Organization on the Endothelial Cell Surface Leads to Diverse Models of Activation by VEGF

    Scientists found that surface VEGF receptor-2 (VEGFR-2) could be mobile or exhibit restricted mobility and be monomeric or non-monomeric, with a complex interplay between the two.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Markers for Ca++-Induced Terminal Differentiation of Keratinocytes In Vitro Under Defined Conditions

    Researchers demonstrated that among 18 markers of terminally differentiated keratinocytes of stratum granulosum and stratum corneum in vivo, only four (CDSN, KPRP, LCE1C, and SPRR4) have reproduced their expression pattern in vitro.
    [Experimental Dermatology]

    Abstract

    Exploitation of Filamentous and Picoplanktonic Cyanobacteria for Cosmetic Applications: Potential to Improve Skin Structure and Preserve Dermal Matrix Components

    Filamentous and picoplanktonic cyanobacteria extracts were analyzed for their pigment profile, phenolic content, antioxidant potential, cytotoxicity against keratinocytes, fibroblasts, endothelial cells and capacity to inhibit hyaluronidase.
    [Marine Drugs]

    Full Article

    An On-Chip Wound Healing Assay Fabricated by Xurography for Evaluation of Dermal Fibroblast Cell Migration and Wound Closure

    Lab-on-a-chip technology was used to investigate the effects of basic fibroblast growth factor, mitomycin C, MEK1/2 inhibitor and fetal calf serum on human dermal fibroblast cell migration.
    [Scientific Reports]

    Full Article

    Hair Growth Activity of Three Plants of the Polynesian Cosmetopoeia and Their Regulatory Effect on Dermal Papilla Cells

    The proliferative activity of Bidens pilosa, Calophyllum inophyllum and Fagraea berteroana on dermal papilla cells was assessed via MTT assay and molecular targets were evaluated by RT-qPCR analysis of seven factors involved in the modulation of the hair cycle, CCND1, LEF1, DKK1, WNT5A PPARD, TGFÎ’1, PPARD and RSPO2.
    [Molecules]

    Full Article

    SKIN CANCERS & DISORDERS

    EZH2-Dependent Epigenetic Modulation of Histone H3 Lysine-27 Contributes to Psoriasis by Promoting Keratinocyte Proliferation

    Scientists found that EZH2 and H3K27me3 were both overexpressed in the epidermis of psoriatic lesional skin compared to normal skin. In vitro, the expression of EZH2 and H3K27me3 was stimulated in human keratinocytes treated with a mixture of psoriasis-related cytokines pool.
    [Cell Death & Disease]

    Full Article

    Beta-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism

    The authors showed that downregulation of galcb, a zebrafish orthologue of human beta-galactosylceramidase (GALC), affects melanoblast and melanocyte differentiation in zebrafish embryos, suggesting a possible role for GALC in melanoma.
    [Cancer Research]

    Abstract

    The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell Carcinoma Cells

    Researchers presented preclinical data on domatinostat efficacy and mode of action in merkel cell carcinoma. Single-cell RNA-sequencing revealed a distinct gene expression signature of antigen processing and presentation, cell cycle arrest, and execution phase of apoptosis upon treatment.
    [Journal of Investigative Dermatology]

    Full Article

    miR-146a-5p Impairs Melanoma Resistance to Kinase Inhibitors by Targeting COX2 and Regulating NFkB-Mediated Inflammatory Mediators

    The miR-146a-5p-regulated NFkB signaling network was identified in drug-resistant cell lines and melanoma tumor samples by expression profiling and knock-in and knock-out studies.
    [Cell Communication and Signaling]

    Full ArticleGraphical Abstract

    Virtual Conference Exhibition: Organoids
    REVIEWS

    Psoriasis: Pathological Mechanisms, Current Pharmacological Therapies, and Emerging Drug Delivery Systems

    Investigators highlight nanotechnology-related developments for psoriasis treatment, including patented delivery systems and therapeutics currently in clinical trials.
    [Drug Discovery Today]

    Abstract

    Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment

    The authors present the oncogenic protein tyrosine phosphatases contributing to melanoma progression and provide, where available, a description of new inhibitory strategies designed against these enzymes and possibly useful in melanoma treatment.
    [Cancers]

    Full ArticleGraphical Abstract

    INDUSTRY AND POLICY NEWS

    Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) versus Opdivo in Resected High-Risk Melanoma Patients

    Bristol Myers Squibb announced results for the co-primary endpoint for CheckMate -915, a randomized Phase III study evaluating Opdivo plus Yervoy versus Opdivo for patients who had a complete surgical removal of stage IIIb/c/d or stage IV melanoma.
    [Bristol Myers Squibb]

    Press Release

    AiViva Biopharma, Inc. Initiates Phase I/II Clinical Trial of AIV001 for Nonmelanoma Skin Cancer

    AiViva Biopharma Inc announced that it had begun dosing patients diagnosed with superficial or nodular basal cell carcinoma with AIV001. AIV001 is AiViva’s novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions.
    [AiViva Biopharma, Inc.]

    Press Release

    FEATURED EVENT

    10 Million Reasons to Defeat Cancer 2020 – Abbott World Summit

    October 13 – October 14
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Scientist Position – Skin Immunology

    University of California, Davis – Sacramento, California, United States

    Research Assistant – Melanoma Immunity

    Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States

    Postdoctoral Fellow – Wound Healing

    University of British Columbia- Vancouver, British Columbia, Canada

    Postdoctoral Scientist – Psoriasis Center for Research Translation

    Case Western Reserve University- Cleveland, Ohio, United States

    Postdoctoral Fellowship – Cutaneous Biology

    University of Michigan- Ann Arbor, Michigan, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Dermal Cell News Archives Contact Us
    Dermal Cell News Twitter